目的：对比分析玻璃体腔注射雷珠单抗和康柏西普治疗糖尿病黄斑水肿的疗效。

方法：回顾分析2015-01/2016-01于我院就诊的糖尿病黄斑水肿患者110例110眼，按照治疗方式不同分为两组，其中55例55眼予以雷珠单抗玻璃体腔注射(雷珠单抗组)，55例55眼予以康柏西普玻璃体腔注射(康柏西普组)，两组患者均每月注射1次，连续注射3次，随访6mo。比较治疗前和治疗后1、3、6mo两组间视力、黄斑厚度变化，以及术后患者舒适度、临床疗效、并发症情况。

结果：治疗前两组患者间LogMAR视力比较，差异无统计学意义(P>0.05)； 治疗后1mo两组患者视力显著改善，较治疗前比较差异有统计学意义(F=42.06、64.02，P<0.01)，但两组间比较差异无统计学意义(P>0.05)； 治疗后3、6mo，康柏西普组视力明显较雷珠单抗组优(P<0.05)。治疗前两组患者间黄斑厚度比较，差异无统计学意义(P>0.05)； 治疗后1mo，两组患者黄斑中心凹区厚度较治疗前降低，差异有统计学意义(P<0.01)； 治疗后3、6mo，康柏西普组较雷珠单抗组下降幅度更大，差异具有统计学意义(P<0.05)。两组患者术后随时间推移舒适度好转，且组间差异无统计学意义(P>0.05)。雷珠单抗组(87.3%、1.8%)和康柏西普组(85.5%、3.6%)临床总有效率和并发症发生率比较，差异无统计学意义(P>0.05)。

结论：康柏西普治疗糖尿病黄斑水肿患者早期视力改善明显，黄斑厚度下降明显，且治疗后3、6mo康柏西普效果较好，疗效更持久。

METHODS: Retrospectively analyzed the clinical data of 110 patients(110 eyes)with diabetic macular edema treated in our hospital from January 2015 to January 2016, divided them into two groups according to the different treatment. Of these, treated 55 eyes with ranibizumab intravitreal injections(ranibizumab group)and the other with conbercept intravitreal injections(conbercept group), the injection came once a month for 8 continuous months with a 6-month follow-up. Compared the changes of visual acuity, macular thickness, postoperative comfort, clinical efficacy and complications between the two groups after treatment.

RESULTS: There was no significant difference in LogMAR visual acuity between the two groups before treatment(P>0.05). The visual acuity of the patients in the ranibizumab group and conbercept group were significantly improved after 1mo treatment, F were 42.06 and 64.02 respectively(P<0.01), but there was no significant difference between the two groups after 1mo treatment(P>0.05). The visual acuity of the conbercept group was significantly higher than that of the ranibizumab group after 3 and 6mo treatment(P<0.05). There was no significant difference in macular thickness between the two groups before treatment(P>0.05), the thickness of the macular fovea in the ranibizumab group and conbercept group was lower than that before treatment, there were statistically significant differences(P<0.01); the decline range of conbercept group were more than those of the ranibizumab group after 3 and 6mo(P<0.05). Patients comfort of the two groups improved with the passage of time after surgery, and there was no significant difference between the two groups(P>0.05), there were no significant differences in the total effective rate and complication of the ranibizumab group(87.3%, 1.8%)and the conbercept group(85.5%, 3.6%)(P>0.05).

CONCLUSION: In the treatment of diabetic macular edema, the early vision of patients with diabetic macular edema increases significantly, and the macular thickness decreases significantly. Conbercept works better and has a longer lasting effect after 3 and 6mo treatment, and conbercept is more economical.